NASDAQ:NVCR - Novocure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.87 -1.51 (-3.00 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$50.38
Today's Range$48.57 - $49.97
52-Week Range$26.02 - $56.67
Volume435,900 shs
Average Volume658,976 shs
Market Capitalization$4.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.32 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$4.68 billion
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable

Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) released its earnings results on Thursday, May, 2nd. The medical equipment provider reported ($0.13) EPS for the quarter, meeting analysts' consensus estimates of ($0.13). The medical equipment provider earned $73.31 million during the quarter, compared to the consensus estimate of $72.85 million. Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Novocure's quarterly revenue was up 40.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.23) earnings per share. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Novocure.

What price target have analysts set for NVCR?

7 analysts have issued 12-month price objectives for Novocure's stock. Their forecasts range from $36.00 to $63.00. On average, they expect Novocure's stock price to reach $48.7143 in the next year. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

What are Wall Street analysts saying about Novocure stock?

Here are some recent quotes from research analysts about Novocure stock:
  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (3/19/2019)
  • 2. Mizuho analysts commented, "We currently model initial revenue for this indication starting in late 2019." (12/6/2018)

Has Novocure been receiving favorable news coverage?

Media stories about NVCR stock have trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (10.90%), Baillie Gifford & Co. (8.41%), BlackRock Inc. (5.02%), Renaissance Technologies LLC (1.94%), Macquarie Group Ltd. (1.21%) and Wells Fargo & Company MN (1.10%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which institutional investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Westfield Capital Management Co. LP, TimesSquare Capital Management LLC, Peregrine Capital Management LLC, Morgan Stanley, Rhenman & Partners Asset Management AB, Macquarie Group Ltd. and Hartline Investment Corp. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Insider Buying and Selling for Novocure.

Which institutional investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Wells Fargo & Company MN, Granite Investment Partners LLC, Federated Investors Inc. PA and Spark Investment Management LLC. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $48.87.

How big of a company is Novocure?

Novocure has a market capitalization of $4.68 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  644
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel